Kraig Biocraft Laboratories In Financials
This page shows Kraig Biocraft Laboratories In (KBLB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
With operating cash burn near -$1.8M and minimal capital spending, the business is financed by balance-sheet stretch rather than self-funding.
From FY2023 through FY2025, free cash flow stayed almost the same as operating cash flow—about-$1.3M to-$1.8M —while annual capex was only a few thousand dollars. That pairing means the cash drain is coming from the operating model itself, not from a temporary buildout of assets, and it makes the recurring losses harder to dismiss as accounting noise.
FY2025 carried
The spending mix is also revealing: SG&A rose to
Financial Health Signals
Kraig Biocraft Laboratories In does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Kraig Biocraft Laboratories In passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.
Kraig Biocraft Laboratories In reported a net loss of $3.6M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Kraig Biocraft Laboratories In reported an operating loss of $3.4M against $571K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Kraig Biocraft Laboratories In's EBITDA was -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 9.9% from the prior year.
Kraig Biocraft Laboratories In reported -$3.6M in net income in fiscal year 2025. This represents a decrease of 6.6% from the prior year.
Kraig Biocraft Laboratories In earned $0.00 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Kraig Biocraft Laboratories In recorded an outflow of $1.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 2.7% from the prior year.
Kraig Biocraft Laboratories In held $1.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Kraig Biocraft Laboratories In invested $166K in research and development in fiscal year 2025. This represents an increase of 0.8% from the prior year.
Kraig Biocraft Laboratories In invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 27.2% from the prior year.
Not reported for fiscal year 2025.
KBLB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $402K+312.7% | $97K+205.5% | $32K | $0 | $0 | $0 | $0 | $0 |
| R&D Expenses | N/A | $166K+0.8% | $164K-30.9% | $238K+34.8% | $176K-10.8% | $198K+123.5% | $88K-60.3% | $223K+50.6% | $148K-42.8% | $259K-34.8% | $397K-8.1% | $432K-1.7% | $440K-10.2% | $489K | N/A | $251K |
| SG&A Expenses | N/A | $2.0M+12.1% | $1.7M+20.2% | $1.5M+76.2% | $825K-44.8% | $1.5M-57.5% | $3.5M+148.8% | $1.4M+174.1% | $516K | N/A | $1.7M+88.6% | $921K+2.8% | $896K-31.6% | $1.3M+245.3% | $379K-51.8% | $787K |
| Operating Income | N/A | -$3.4M-9.8% | -$3.1M-17.6% | -$2.6M-23.3% | -$2.1M+23.1% | -$2.8M+39.1% | -$4.5M-72.9% | -$2.6M-173.1% | -$960K | N/A | N/A | N/A | -$1.8M | N/A | N/A | N/A |
| Interest Expense | N/A | $571K+7.8% | $530K+9.3% | $485K+214.8% | $154K-35.3% | $238K+4245.9% | $5K-98.1% | $294K+28.6% | $229K+29.3% | $177K+27.0% | $139K+37.3% | $102K+46.6% | $69K+5.6% | $66K+43.5% | $46K | $0 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$3.6M-6.6% | -$3.4M-12.2% | -$3.0M+21.1% | -$3.8M+52.2% | -$8.0M-61.8% | -$5.0M-70.8% | -$2.9M-148.9% | -$1.2M | N/A | N/A | N/A | -$1.9M | N/A | N/A | N/A |
| EPS (Diluted) | — | $0.00 | $0.00 | $0.00 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KBLB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6M+70.4% | $1.5M-53.4% | $3.2M-29.3% | $4.6M+51.3% | $3.0M+136.6% | $1.3M+70.1% | $751K+951.9% | $71K-37.7% | $114K-70.2% | $384K+25.8% | $305K-43.4% | $539K+73.3% | $311K+295.2% | $79K-64.8% | $224K |
| Current Assets | $1.9M+152.4% | $740K-71.2% | $2.6M-35.4% | $4.0M+68.4% | $2.4M+188.7% | $819K+422.7% | $157K+662.7% | $21K-57.6% | $48K-85.4% | $332K+38.9% | $239K-51.9% | $496K+66.9% | $297K+377.4% | $62K-69.1% | $201K |
| Cash & Equivalents | $1.8M+165.9% | $673K-73.6% | $2.6M-33.9% | $3.9M+64.0% | $2.4M+188.3% | $817K+553.4% | $125K+812.8% | $14K-24.5% | $18K-93.9% | $299K+25.5% | $238K-51.9% | $495K+67.6% | $295K+449.2% | $54K-72.5% | $195K |
| Inventory | $29K+322.2% | $7K0.0% | $7K+4.6% | $7K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $26K-18.8% | $32K | $0 | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.6M+9.4% | $9.7M+8.0% | $8.9M+10.5% | $8.1M-2.7% | $8.3M+5.9% | $7.9M+27.9% | $6.1M+35.5% | $4.5M+29.8% | $3.5M+27.2% | $2.7M+24.6% | $2.2M+24.8% | $1.8M+16.7% | $1.5M+24.7% | $1.2M+7.4% | $1.1M |
| Current Liabilities | $10.4M+8.6% | $9.6M+8.2% | $8.9M+10.1% | $8.1M-1.1% | $8.2M+9.6% | $7.5M+33.4% | $5.6M+23.3% | $4.5M+29.8% | $3.5M+27.2% | $2.7M+24.6% | $2.2M+24.8% | $1.8M+16.7% | $1.5M+25.7% | $1.2M+7.8% | $1.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $9K | N/A |
| Total Equity | -$8.0M+1.8% | -$8.1M-42.8% | -$5.7M-62.0% | -$3.5M+33.5% | -$5.3M+19.4% | -$6.6M-22.0% | -$5.4M-20.8% | -$4.5M-32.1% | -$3.4M-43.0% | -$2.4M-24.5% | -$1.9M-54.8% | -$1.2M-2.0% | -$1.2M-5.9% | -$1.1M-25.1% | -$906K |
| Retained Earnings | -$56.7M-6.8% | -$53.1M-6.8% | -$49.7M-6.5% | -$46.7M-9.0% | -$42.8M-23.1% | -$34.8M-16.7% | -$29.8M-10.8% | -$26.9M-4.5% | -$25.7M-10.0% | -$23.4M-15.1% | -$20.3M-11.7% | -$18.2M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Goodwill.
KBLB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0M | -$1.8M+2.7% | -$1.8M-47.8% | -$1.2M+34.1% | -$1.9M-4.8% | -$1.8M-43.5% | -$1.3M-15.3% | -$1.1M-362.9% | -$235K | N/A | -$1.0M-4.6% | -$968K-7.0% | -$905K-13.0% | -$800K | N/A | -$556K |
| Capital Expenditures | $44K | $5K+27.2% | $4K-33.7% | $6K+27.4% | $5K-94.8% | $97K | N/A | $101K+780.4% | $11K-63.3% | $31K+1152.7% | $2K-93.7% | $39K-6.0% | $42K+1103.7% | $3K | $0-100.0% | $1K |
| Free Cash Flow | -$2.1M | -$1.8M+2.7% | -$1.8M-47.4% | -$1.3M+33.9% | -$1.9M+0.3% | -$1.9M | N/A | -$1.2M-382.3% | -$246K | N/A | -$1.0M-0.7% | -$1.0M-6.4% | -$946K-17.8% | -$804K | N/A | -$557K |
| Investing Cash Flow | $252K | $438K+10431.2% | -$4K+33.7% | -$6K-27.4% | -$5K+99.1% | -$547K | N/A | -$101K-780.4% | -$11K+63.3% | -$31K-1152.7% | -$2K+93.7% | -$39K+6.0% | -$42K-1103.7% | -$3K-1708.9% | -$192+97.3% | -$7K |
| Financing Cash Flow | $4.4M | $2.5M+7102.3% | -$35K+41.3% | -$60K-101.8% | $3.4M-12.5% | $3.9M+99.6% | $1.9M+49.7% | $1.3M+437.2% | $242K-49.6% | $480K-55.3% | $1.1M+43.3% | $750K-34.6% | $1.1M+9.6% | $1.0M | N/A | $666K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KBLB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -239.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -291.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -141.2%+84.6pp | -225.8%-132.1pp | -93.7%-9.7pp | -84.0%+182.2pp | -266.3%+123.0pp | -389.2%-1.7pp | -387.5%+1250.1pp | -1637.6% | N/A | N/A | N/A | -347.4% | N/A | N/A | N/A |
| Current Ratio | 0.18+0.1x | 0.08-0.2x | 0.29-0.2x | 0.49+0.2x | 0.29+0.2x | 0.11+0.1x | 0.030.0x | 0.000.0x | 0.01-0.1x | 0.120.0x | 0.11-0.2x | 0.28+0.1x | 0.20+0.1x | 0.05-0.1x | 0.18 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -61.4% | N/A | -3183.9% | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$8.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.18), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Kraig Biocraft Laboratories In Ranks
Frequently Asked Questions
Is Kraig Biocraft Laboratories In profitable?
No, Kraig Biocraft Laboratories In (KBLB) reported a net income of -$3.6M in fiscal year 2025.
What is Kraig Biocraft Laboratories In's EBITDA?
Kraig Biocraft Laboratories In (KBLB) had EBITDA of -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Kraig Biocraft Laboratories In's free cash flow?
Kraig Biocraft Laboratories In (KBLB) recorded an outflow of $1.8M in free cash flow during fiscal year 2025. This represents a 2.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Kraig Biocraft Laboratories In's operating cash flow?
Kraig Biocraft Laboratories In (KBLB) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Kraig Biocraft Laboratories In's total assets?
Kraig Biocraft Laboratories In (KBLB) had $2.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Kraig Biocraft Laboratories In's capital expenditures?
Kraig Biocraft Laboratories In (KBLB) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Kraig Biocraft Laboratories In spend on research and development?
Kraig Biocraft Laboratories In (KBLB) invested $166K in research and development during fiscal year 2025.
What is Kraig Biocraft Laboratories In's current ratio?
Kraig Biocraft Laboratories In (KBLB) had a current ratio of 0.18 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Kraig Biocraft Laboratories In's return on assets (ROA)?
Kraig Biocraft Laboratories In (KBLB) had a return on assets of -141.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Kraig Biocraft Laboratories In's cash runway?
Based on fiscal year 2025 data, Kraig Biocraft Laboratories In (KBLB) had $1.8M in cash against an annual operating cash burn of $1.8M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Kraig Biocraft Laboratories In's debt-to-equity ratio negative or not reported?
Kraig Biocraft Laboratories In (KBLB) has negative shareholder equity of -$8.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Kraig Biocraft Laboratories In's Piotroski F-Score?
Kraig Biocraft Laboratories In (KBLB) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kraig Biocraft Laboratories In's earnings high quality?
Kraig Biocraft Laboratories In (KBLB) reported a net loss of $3.6M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Kraig Biocraft Laboratories In cover its interest payments?
Kraig Biocraft Laboratories In (KBLB) reported an operating loss of $3.4M against $571K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.